Regencell Bioscience Holdings Ltd is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Regencell Bioscience Holdings Ltd valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds26 adding, 18 cuttingOf 4 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 138.1% while net income fell 226.5%: a 88pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Price chart
- 1 day-1.2%
- 1 week-16.7%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.02
Growth
- Share count change
- +0.0%
Cash
- Free cash flow (TTM)
- -$7.8M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for RGC from the sources we follow. See filings →
Valuation models
We value Regencell Bioscience Holdings Ltd as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.86 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Regencell Bioscience Holdings Ltd with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Regencell Bioscience Holdings Ltd: too few analysts cover it.
Positioning
- Short interest
- 0.8% of tradable shares
- Days to cover
- 1.71 at average volume
- Short interest, 1 month
- −45% to October 15, 2026
- Held by institutions
- 0% of shares
- Held by insiders
- 88.5% of shares
- Employees
- 10 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $14m of assets due within a year against $1m of liabilities due within a year.
- Short-term assets cover long-term liabilities $14m short-term assets against $59,499 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +0.0%
- year over year
Who owns it
Funds buying and selling- Reported value
- $8.6M
- Institutions reporting
- 35
- Shares held vs prior quarter
- ▲ 117.1%
- Positions opened / closed
- 16 / 12
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Geode Capital Management, LLC | $2.6M | 422K | 30.0% | ▲ 1.6% |
| Alyeska Investment Group, L.P. | $2.5M | 416K | 29.6% | New |
| Legal & General Group PLC | $778,974 | 128K | 9.1% | ▲ 1192.5% |
| Jane Street Group, LLC | $598,940 | 98K | 7.0% | New |
| Xtx Topco Ltd | $365,771 | 60K | 4.3% | New |
| Amundi | $287,198 | 47K | 3.4% | ▲ 448.7% |
| UBS Group AG | $263,137 | 43K | 3.1% | ▲ 80.9% |
| Quadrature Capital Ltd | $254,258 | 42K | 3.0% | New |
| Susquehanna International Group, LLP | $140,856 | 23K | 1.6% | New |
| Squarepoint Ops LLC | $134,199 | 22K | 1.6% | ▼ 17.2% |
| Fox Run Management, L.L.C. | $126,008 | 21K | 1.5% | New |
| CIBC Asset Management Inc | $93,128 | 15K | 1.1% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Regencell Bioscience Holdings Ltd's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Regencell Bioscience Holdings Ltd in brief
- What does Regencell Bioscience Holdings Ltd do?
- Regencell Bioscience Holdings Ltd is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.
- What is Regencell Bioscience Holdings Ltd's stock ticker?
- Regencell Bioscience Holdings Ltd trades under the ticker RGC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Regencell Bioscience Holdings Ltd's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Geode Capital Management, LLC, Alyeska Investment Group, L.P. and Legal & General Group PLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Follow research on Regencell Bioscience Holdings Ltd
New research on the companies we cover arrives in the weekly email. Free, one email a week.